Drug intelligence / Profile preview

midazolam + fentanyl + rocuronium

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination of three pharmaceutical agents—midazolam, fentanyl, and rocuronium—commonly used for the induction of anesthesia, particularly in rapid sequence intubation (RSI) and emergency airway management. - **Midazolam** is a short-acting benzodiazepine that acts as a central nervous system depressant by enhancing the effect of gamma-aminobutyric acid (GABA) at the GABA(A) receptor, producing sedation, anxiolysis, amnesia, and muscle relaxation. - **Fentanyl** is a potent synthetic opioid analgesic that primarily acts as an agonist at the mu-opioid receptor to provide analgesia and additional sedation. - **Rocuronium** is a non-depolarizing neuromuscular blocking agent that competitively inhibits acetylcholine at nicotinic receptors on skeletal muscle endplates, resulting in paralysis to facilitate intubation or surgery. This combination regimen provides rapid onset of unconsciousness (midazolam), profound analgesia (fentanyl), and muscular relaxation/paralysis (rocuronium), making it suitable for procedures requiring secure airway control such as after cardiac arrest or in trauma settings[1][2][3]. The combination has been shown to be effective for prehospital or emergency department anesthesia but may cause reductions in systolic blood pressure post-induction[2].

02

Targets

GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)Nicotinic Acetylcholine ReceptorMOR (Mu opioid receptor)

Beyond the preview

Go deeper on midazolam + fentanyl + rocuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on midazolam + fentanyl + rocuronium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call